Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Ovidiu Ionut Vornicu"'
Autor:
Anne-Sophie Dincq, Michael Hardy, Lionel Pochet, Anne-Laure Sennesael, Ovidiu Ionut Vornicu, Olivier Deceuninck, Romain Siriez, Sarah Lessire, Jonathan Douxfils, François Mullier
Publikováno v:
International journal of laboratory hematology, Vol. 42, no. 4, p. 394-402 (2020)
Introduction: Estimation of residual apixaban plasma concentrations may be requested in the management of emergencies. This study aims at assessing the performance of specific anti-Xa assays calibrated with apixaban on real-life samples with low apix
Autor:
Julien Favresse, Michael Hardy, Charles-Marc Samama, A L Sennesael, M A van Dievoet, Ovidiu Ionut Vornicu, Sarah Lessire, Anne-Sophie Dincq, François Mullier, Jonathan Douxfils
Publikováno v:
Expert opinion on biological therapy, Vol. 19, no. 5, p. 387-397 (2019)
INTRODUCTION: Andexanet alfa is a recombinant modified factor Xa protein that has been developed to reverse factor Xa inhibitors. Since May 2018, the FDA has approved its utilization in patients treated with apixaban and rivaroxaban in case of life-t
Autor:
Anne-Sophie Larock, Sarah Lessire, Jonathan Douxfils, Ovidiu Ionut Vornicu, Anne-Sophie Dincq, François Mullier, Jean-Michel Dogné
Publikováno v:
Expert opinion on biological therapy. 17(10)
Idarucizumab is a specific antagonist for dabigatran etexilate (DE). The recent market authorization of idarucizumab in Europe and the USA may reassure prescribers of DE, as it can increase the safety of the emergency management of patients taking th